[144] SOPHiA GENETICS SA SEC Filing

Rhea-AI Filing Summary

Form 144 overview: SOPHiA GENETICS SA (ticker SOPH) has filed a Form 144 indicating the proposed sale of insider-held shares under Rule 144 of the Securities Act of 1933.

• Seller & relationship: The filing lists one unnamed insider ("person for whose account the securities are to be sold"). No further relationship data is provided in the snippet.
• Securities to be sold: 18,443 shares of common stock.
• Estimated market value: USD 56,066.72, implying an indicative share price of roughly USD 3.04.
• Broker: Morgan Stanley Smith Barney LLC, Executive Financial Services, New York.
• Planned trade date & venue: On or about 20 June 2025 on the NASDAQ.
• Shares outstanding: 66,687,085. The proposed sale represents approximately 0.028% of total shares outstanding—not material from a dilution perspective.
• Source of shares: Restricted Stock Units acquired 18 June 2025; not a gift.
• Prior 3-month sales: The filer reports "Nothing to Report," indicating no other recent insider sales by this individual that must be aggregated.

Investor takeaway: The filing signals a routine disposal of a small block of shares by an insider. Given the limited size relative to total float and the absence of any cited adverse information, the market impact is likely negligible. Nevertheless, investors monitoring insider activity may note the transaction when evaluating sentiment and liquidity conditions.

Positive

• None.

Negative

• Insider disposition: Filing signals intended sale of shares, which some investors could view as a modestly negative sentiment indicator, even though the amount is immaterial.

Insights

Financial Analyst

TL;DR: Small insider sale (18,443 shares) is routine, de-minimis to float; no material signal.

The proposed sale totals about USD 56k, representing 0.028% of SOPH’s 66.7 million shares outstanding. This aligns with normal liquidity management after RSU vesting. No earnings or operational data accompany the filing, and the insider expressly certifies no undisclosed adverse information. From a valuation or liquidity viewpoint, the transaction is immaterial and unlikely to affect trading multiples, bid-ask spreads, or institutional ownership dynamics.

Corporate Governance Expert

TL;DR: Governance impact negligible; filing fulfills disclosure duties under Rule 144.

Rule 144 requires advance notice for certain insider resales. The filer adheres to procedural norms—listing broker, dates, and share counts—and affirms no possession of non-public material information. No 10b5-1 plan date is provided, so trade timing discretion may still exist, but volume limits are far below Rule 144 thresholds. Overall, the event does not raise governance red flags or suggest imminent corporate developments.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	18443	56066.72	66687085	06/20/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/18/2025	Restricted Stock Units	Issuer			18443	06/18/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many SOPH shares are being sold under this Form 144?

18,443 common shares are proposed for sale.

What is the aggregate market value of the SOPH shares to be sold?

The filing lists an aggregate value of USD 56,066.72 for the 18,443 shares.

When is the planned sale date for these SOPH shares?

The approximate sale date stated is 20 June 2025.

What percentage of SOPHiA GENETICS SA’s outstanding shares does the sale represent?

The 18,443 shares equal roughly 0.028% of the 66,687,085 shares outstanding.

Which broker will execute the sale of SOPH shares?

Morgan Stanley Smith Barney LLC, Executive Financial Services, New York, is named as broker.

Were any other insider sales reported in the past three months?

The filer states "Nothing to Report" for prior 3-month sales.